Mizuho Raises Solventum (NYSE:SOLV) Price Target to $82.00

Solventum (NYSE:SOLV - Get Free Report) had its target price upped by stock analysts at Mizuho from $70.00 to $82.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a "neutral" rating on the stock. Mizuho's price objective indicates a potential upside of 8.34% from the stock's previous close.

Several other research firms have also recently weighed in on SOLV. Morgan Stanley increased their price objective on Solventum from $60.00 to $73.00 and gave the stock an "equal weight" rating in a report on Monday, November 11th. The Goldman Sachs Group raised their price target on Solventum from $63.00 to $71.00 and gave the stock a "sell" rating in a research note on Monday. Wells Fargo & Company boosted their price objective on shares of Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a research report on Friday, February 28th. Bank of America raised their target price on shares of Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 26th. Finally, Piper Sandler boosted their price target on shares of Solventum from $75.00 to $84.00 and gave the company a "neutral" rating in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $79.86.

Solventum Trading Down 2.8 %

Shares of NYSE:SOLV traded down $2.14 during midday trading on Monday, hitting $75.69. 1,066,184 shares of the stock traded hands, compared to its average volume of 1,033,113. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The business's 50 day moving average is $73.25 and its two-hundred day moving average is $70.39. The stock has a market capitalization of $13.08 billion and a PE ratio of 27.52. Solventum has a one year low of $47.16 and a one year high of $96.05.

Hedge Funds Weigh In On Solventum

Large investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in Solventum by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 16,266,893 shares of the company's stock valued at $1,074,591,000 after buying an additional 75,631 shares during the last quarter. Trian Fund Management L.P. increased its holdings in shares of Solventum by 18.8% during the fourth quarter. Trian Fund Management L.P. now owns 8,462,819 shares of the company's stock valued at $559,054,000 after acquiring an additional 1,336,564 shares in the last quarter. State Street Corp boosted its stake in Solventum by 3.1% in the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company's stock worth $425,818,000 after purchasing an additional 185,938 shares in the last quarter. Geode Capital Management LLC raised its holdings in Solventum by 3.4% in the fourth quarter. Geode Capital Management LLC now owns 3,460,405 shares of the company's stock worth $227,992,000 after buying an additional 112,686 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Solventum in the 4th quarter worth $203,740,000.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.